Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report

IF 1.5 Q4 ONCOLOGY

Cancer reports Pub Date : 2024-11-15 DOI:10.1002/cnr2.2149

Danilo De Novellis, Pio Zeppa, Elisabetta Maffei, Valentina Giudice, Carmine Selleri, Bianca Serio

{"title":"Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report","authors":"Danilo De Novellis, Pio Zeppa, Elisabetta Maffei, Valentina Giudice, Carmine Selleri, Bianca Serio","doi":"10.1002/cnr2.2149","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and <i>JAK2</i>-mutated myeloproliferative neoplasm with marked splenomegaly.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 11","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564862/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.2149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.

Case Presentation

Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly.

Conclusions

We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.

Abstract Image

查看原文本刊更多论文

达拉单抗治疗髓外肺浆细胞瘤的疗效：病例报告

导言：多发性骨髓瘤（MM）伴有肺髓外疾病非常罕见，通常预后较差：多发性骨髓瘤（MM）伴有肺髓外疾病非常罕见，通常预后较差，目前还没有关于以达拉单抗为基础的治疗方案的数据报道：在这里，一名64岁的肺浆细胞瘤患者接受了达拉单抗治疗，取得了非常好的部分反应，肺部肿块消失，总生存期为16个月。他没有接受自体干细胞移植，因为他有几种合并症，如严重的药物性神经病变和JAK2突变骨髓增生性肿瘤伴明显脾肿大：我们证明了达拉土单抗联合靶向疗法治疗肺癌的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer reports Medicine-Oncology

CiteScore

2.70

自引率

5.90%

发文量

160

审稿时长

17 weeks